Treatment of Fulminant Meningococcemia with Recombinant Tissue Plasminogen Activator

Successful Endovascular Therapy for Acute Basilar Thrombosis in an Adolescent

“…38 In children receiving thrombolytic treatments for noncerebral thrombosis, the incidence of intracranial hemorrhage has been estimated at 1% to 2%, and is likely well below 1% outside the neonatal period. 39 These figures are consistent with those observed in adults undergoing systemic thrombolysis for acute myocardial infarction. 40 …”

4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia

“…The finding that a gene controlling the inhibition of fibrinolysis determines outcome suits perfectly the hypothesis that the pathophysiology of meningococcal sepsis is in part related to disseminated intravascular coagulation that leads to impaired organ perfusion and eventually to multiorgan failure [28,31]. This hypothesis is supported by observations that plasma concentrations of PAI-1 are significantly higher in patients with sepsis than with meningitis [13].…”

“…However, in a restrospective multicentre study in patients with severe meningococcal infection, a high risk of intracerebral bleedings has been described with the unrestricted systemic use of this substance [31,32].…”

Pediatric Sepsis: Genetic Considerations

“…94 The significance of this genetic variant lies in the fact that the administration of tPA and APC is a therapeutic option that might improve outcomes. [95][96][97][98] Fibrinogen Fibrinogen, or factor I, is synthesized in the liver. As part of the coagulation cascade, it is converted into fibrin by thrombin.…”